Osteoporosis in Elderly Patients

  • Paolo FalaschiEmail author
  • Stefania Giordano
Part of the Practical Issues in Geriatrics book series (PIG)


Osteoporosis is a systemic bone disease affecting numerous people all over the world, causing fragility fractures, especially among the elderly. In order to reach a complete diagnosis, it is necessary to perform Dual X-Ray Absorptiometry (DXA) to evaluate Bone Mineral Density (BMD), an X-Ray of the dorsal and lumbar spine to investigate the presence of asymptomatic vertebral fractures, laboratory tests to exclude secondary forms of osteoporosis, and an accurate medical history, since several risk factors may be involved. The general management of this pathology includes prevention of further falls as well as the administration of calcium, vitamin D and protein supplements. Many drugs that permit a customised strategy – fundamental to improving treatment-adherence rates, frequently low in elderly patients – are available for the pharmacological treatment of the pathology.


Bone Mineral Density Vertebral Fracture Fracture Risk Osteoporotic Fracture Zoledronic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S et al (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMedGoogle Scholar
  2. 2.
    Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefPubMedGoogle Scholar
  3. 3.
    Johnell O, Kanis J et al (2006) An estimate of the worldwide prevalence and disabilityassociated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMedGoogle Scholar
  4. 4.
    Kanis J, Borgstrom F, De Leat C, Johansson H, Johnell O, Jonsson B, Odea A, Zethraeus N, Pfleger B, Khaltaev N et al (2005) Assesment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMedGoogle Scholar
  5. 5.
    Strom O, Borgstrom F, Kanis J, Compston J, Cooper C, McCloskey E, Jonsson B (2011) Osteoporosis: burden, healthcare provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155CrossRefPubMedGoogle Scholar
  6. 6.
    Kanis J, Compston J, Cooper C et al (2012) The burden of fractures in the European Union in 2010. Osteoporos Int 23:S57CrossRefGoogle Scholar
  7. 7.
    Cooper C, Atkinson E, Jacobsen S, O’Fallon W, Melton L (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMedGoogle Scholar
  8. 8.
    Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby A (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefPubMedGoogle Scholar
  9. 9.
    Kanis J, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12(12):989–995CrossRefPubMedGoogle Scholar
  10. 10.
    Miller P, Barlas S, Brenneman S, Abbott T, Chen Y, Barrett-Connor E, Siris E (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164:1113–1120CrossRefPubMedGoogle Scholar
  11. 11.
    Hui S, Slemenda C, Johnston C (1998) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809CrossRefGoogle Scholar
  12. 12.
    Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop W, Burke G, McBurnie M (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156CrossRefPubMedGoogle Scholar
  13. 13.
    Tom S, Adachi J, Anderson F Jr, Boonen S, Chapurlat R, Compston J, Cooper C, Gehlbach S, Greenspan S, Hooven F, Nieves J, Pfeilschifter J, Roux C, Silverman S, Wyman A, LaCroix A (2013) Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc 61:327–334CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kanis J, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from UK. Osteoporos Int 19:385–397CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kanis J, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRefPubMedGoogle Scholar
  16. 16.
    Leslie W, Lix L, Johansson H, Oden A, McCloskey E, Kanis J (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847CrossRefPubMedGoogle Scholar
  17. 17.
    Hiligsmann M, Kanis J, Compston J, Cooper C, Flamion B, Bergmann P, Body J, Boonen S, Bruyere ODJ, Goemaere S, Kaufman J, Rozenberg S, Reginster J (2013) Health technology assessment in osteoporosis. Calcif Tissue Int 93:1–14CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Howe T, Rochester L, Neil F, Skelton D, Ballinger C (2011) Exercise for improving balance in older people. Cochrane Database Syst Rev 11:CD004963PubMedGoogle Scholar
  19. 19.
    AGS/BGS/AAOS (2001) Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 49:664–672CrossRefGoogle Scholar
  20. 20.
    Michael Y, Whitlock E, Lin J, Fu R, O’Connor E, Gold R (2010) Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 153:815–825CrossRefPubMedGoogle Scholar
  21. 21.
    Rizzoli R, Branco J, Brandi M, Boonen S, Bruyère O, Cacoub P, Cooper C (2014) Management of osteoporosis of the oldest old. Osteoporos Int 25:2507–2529CrossRefPubMedGoogle Scholar
  22. 22.
    Boucher B (2012) The problems of vitamin D insufficiency in older people. Aging Dis 3:313–329PubMedPubMedCentralGoogle Scholar
  23. 23.
    Bischoff-Ferrari H, Willett W, Orav E, Lips P, Meunier P, Lyons R, Flicker L, Wark J, Jackson R, Cauley J, Meyer H, Pfeifer M, Sanders K, Stahelin H, Theiler R, Dawson-Hughes B (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40–49CrossRefPubMedGoogle Scholar
  24. 24.
    Bischoff-Ferrari H, Dawson-Hughes B, Staehelin H, Orav J, Stuck A, Theiler R, Wong J, Egli A, Kiel D, Henschkowski J (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rizzoli R, Boonen S, Brandi N, Bruyer O, Cooper C, Kanis J, Kaufman J, Ringe J, Weryha G, Reginster J (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of 2008 reccomandations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29:305–313CrossRefPubMedGoogle Scholar
  26. 26.
    Bischoff-Ferrari H, Kiel D, Dawson-Hughes B, Orav J, Li R, Spiegelman D, Dietrich T, Willett W (2009) Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 24:935–942CrossRefPubMedGoogle Scholar
  27. 27.
    Bolland M, Avenell A, Baron J, Grey A, MacLennan G, Gamble G, Reid I (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Burckhardt P (2011) Potential negative cardiovascular effects of calcium supplements. Osteoporos Int 22:1645–1647CrossRefPubMedGoogle Scholar
  29. 29.
    Genaro P, Martini L (2010) Effect of protein intake on bone and muscle mass in the elderly. Nutr Rev 68:616–623CrossRefGoogle Scholar
  30. 30.
    Livingstone C (2013) Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clin Sci (Lond) 125:265–280CrossRefGoogle Scholar
  31. 31.
    Ensrud K, Black D, Palermo L, Bauer D, Barrett-Connor E, Quandt S, Thompson DKD (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617–2624CrossRefPubMedGoogle Scholar
  32. 32.
    Greenspan S, Schneider D, McClung M, Miller P, Schnitzer T, Bonin R, Smith M, De Lucca P, Gormley G, Melton M (2002) Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 136:742–746CrossRefPubMedGoogle Scholar
  33. 33.
    Chesnut I, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefPubMedGoogle Scholar
  34. 34.
    Harris S, Blumentals W, Miller P (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237–245CrossRefPubMedGoogle Scholar
  35. 35.
    Reginster J, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654–661CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Boonen S, McClung M, Eastell R, El-Hajj F, Barton I, Delmas P (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832–1839CrossRefPubMedGoogle Scholar
  37. 37.
    Reid I, Brown J, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMedGoogle Scholar
  38. 38.
    Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
  39. 39.
    Lyles K, Colon-Emeric C, Magaziner J et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1–11CrossRefGoogle Scholar
  40. 40.
    Meunier P, Roux C, Seeman EOS, Badurski J, Spector T et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefPubMedGoogle Scholar
  41. 41.
    Reginster J, Seeman E, De Vernejoul M et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822CrossRefPubMedGoogle Scholar
  42. 42.
    Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11:1–134CrossRefPubMedGoogle Scholar
  43. 43.
    Lecart M, Reginster J (2011) Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 12:2533–2552CrossRefPubMedGoogle Scholar
  44. 44.
    Cummings S, San Martin J, McClung M et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMedGoogle Scholar
  45. 45.
    Papapoulos S, Chapurlat R, Libanati C et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRefPubMedGoogle Scholar
  46. 46.
    McCloskey E, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki E, Lorenc R, Libanati C, Kanis J (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX(R). J Bone Miner Res 27(7):1480–1486CrossRefPubMedGoogle Scholar
  47. 47.
    Neer R, Arnaud C, Zanchetta J et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  48. 48.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky G, Mitlak B (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513CrossRefPubMedGoogle Scholar
  49. 49.
    Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten G, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Geriatric UnitSapienza University of Rome, Sant’Andrea HospitalRomeItaly

Personalised recommendations